YD Bio Limited Warrants(YDESW)Earnings, Financials & Key Ratios
YDESW•NASDAQ
$0.21
Price updated Jul 7, 2026
AboutYD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.Show more
- Revenue$510K+45.8%
- EBITDA-$1M-18252.9%
- Net Income-$1M-10509.7%
- EPS (Diluted)0.00
- Gross Margin30.44%-30.5%
- EBITDA Margin-265.93%-12490.7%
- Operating Margin-286.45%-10085.3%
- Net Margin-276.58%-7241.6%
- ROE-42.69%-172.4%
YDESW Price & Volume
YD Bio Limited Warrants (YDESW) stock price & volume — 10-year historical chart
Loading chart...
High Burn Rate Challenges Early Diagnostic Growth
Investment Thesis • Updated N/A
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Rapid Cash Runway Depletion
Key Thesis Takeaways
- YD Bio Limited faces significant execution risk as it attempts to balance a dual-track strategy in cancer diagnostics and regenerative ophthalmology with limited capital resources.
- While the company maintains a debt-free balance sheet, its reliance on a $3.1M cash reserve to fund an operating margin of -286.45% suggests a precarious path toward commercial viability.
- Investors should monitor the potential for significant equity dilution from the warrant structure as the firm seeks to scale its nascent $510,360 revenue base.
Verdict Logic
the company's operating margin of -286.45% and limited $3.1M cash position indicate a high-risk profile that may lead to significant shareholder dilution.
YDESW Growth Metrics
YD Bio Limited Warrants (YDESW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-43.48%
5 Years-43.48%
3 Years-43.48%
Last Year-44.14%
Peers Comparison
Key metrics vs top competitors for YD Bio Limited Warrants (YDESW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.21 | — | — | 45.76% | -276.58% | -42.69% | — | |
| $94.29 | $23.84B | -18.30 | 0.2% | -44.95% | -6.72% | — | |
| $9.46 | $1.56B | 3.72 | 64.69% | -14.73% | — | — | |
| $1.50 | $507.78M | -6.52 | 8.83% | -1605.22% | -127987.5% | — | |
| $0.55 | $133.16M | 7.86 | 726.68% | 14.51% | 61.43% | — | |
| $1.21 | $836.13M | -0.67 | -69.99% | — | -666.47% | — |
Compare YDESW vs Peers
YD Bio Limited Warrants (YDESW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when YDESW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
YDESW Frequently Asked Questions
YD Bio Limited Warrants (YDESW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is YD Bio Limited Warrants's revenue?
YD Bio Limited Warrants (YDESW) reported $0.5M in revenue for fiscal year 2024. This represents a 46% increase from $0.4M in 2023.
How fast is YD Bio Limited Warrants growing?
YD Bio Limited Warrants (YDESW) grew revenue by 45.8% over the past year. This is strong growth.
Is YDESW profitable?
YD Bio Limited Warrants (YDESW) reported a net loss of $1.4M for fiscal year 2024.
Dividend & Returns
What is YDESW's return on equity?
YD Bio Limited Warrants (YDESW) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.
What is YD Bio Limited Warrants's free cash flow?
YD Bio Limited Warrants (YDESW) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.